navarixin
Small moleculeexperimental
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2006 (NCT00441701)
Timeline
Indications
Mechanism of action
- Interleukin-8 receptor AANTAGONIST
CXCR1 antagonist
- Interleukin-8 receptor BANTAGONIST
CXCR2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1- Mol. weight
- 397.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL216981 ↗
- ChEMBLCHEMBL2103864 ↗
Also known as
- 2-hydroxy-n,n-dimethyl-3-(2-((1-(5-methylfuran-2-yl)propyl)amino)-3,4-dioxocyclobut-1-enylamino)benzamide
- mk-7123
- mk-7123
- mk-7123
- navarixin
- navarixin
- navarixin
- navarixin
- navarixin anhydrous
- navarixin anhydrous
- navarixin hydrate
- navarixin hydrate
- ps-291822
- ps-291822
- sch527123
- sch 527123
- sch 527123
- sch 527123
- sch-527123
- sch-527123
- sch-527123
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03473925 | Phase 2 | Apr 10, 2018 | Merck |
| NCT01068145 | Phase 1 | Feb 1, 2010 | Merck |
| NCT01006161 | Phase 2 | Jan 1, 2010 | Merck |
| NCT01006616 | Phase 2 | Oct 1, 2009 | Merck |
| NCT00688467 | Phase 2 | Jun 1, 2008 | Merck |
| NCT00632502 | Phase 2 | May 1, 2008 | Merck |
| NCT00684593 | Phase 2 | Jun 1, 2007 | Merck |
| NCT00441701 | Phase 2 | Dec 1, 2006 | Merck |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 8 | 8 | 2 | 2006 |
1 organizations
Page 1 / 1